Thromboelastography to Monitor Clotting/Bleeding Complications in Patients Treated with the Molecular Adsorbent Recirculating System
Figure 6
No indication for activation of the clotting system by MARS: From a subset of MARS sessions (patient no. 2 and no. 4) frozen plasma samples were available and parameters for thrombin activation were determined. (a) Quantification of F1+2 fragments by ELISA in plasma samples obtained before (prior) during and after the MARS sessions, are presented as box plots. Baseline F1+2 values were significantly above the cut-off value of 1.2 nmol/L (). MARS therapy did not significantly influence F1+2 values over time. (b) Estimation of the endogenous thrombin potential. Samples were as in (a). Line plots present data as mean ± SD for the parameters lag time, endogenous thrombin potential (ETP), maximal response (peak) and the time until the peak is reached (time to peak), , *Indicates .
